Welcome to our dedicated page for Krystal Biotech SEC filings (Ticker: KRYS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Krystal Biotech filings document formal disclosures for a commercial-stage biotechnology company developing and commercializing genetic medicines. Recent 8-K reports furnish quarterly and annual financial results, VYJUVEK net product revenue updates, Regulation FD clinical materials, FDA-related program updates, and commercial launch information for VYJUVEK in Japan.
The company's proxy materials disclose board and shareholder-vote matters, executive compensation, equity awards, ownership information, and governance practices. Together, the filings record how Krystal reports operating performance, capital resources, pipeline and regulatory disclosures, and public-company governance for its HSV-1-based gene therapy platform.
Krystal Biotech director-linked entity sells shares under trading plan
Alta Bioequities, L.P., an entity associated with Krystal Biotech director Daniel Janney, sold a total of 11,803 shares of the company’s common stock in two open-market transactions on February 27, 2026, at weighted average prices of $275.4487 and $276.1665 per share.
The sales were executed under a pre-established Rule 10b5-1 trading plan adopted on November 25, 2025, which is scheduled to terminate on November 5, 2026, subject to early termination. Alta Bioequities, L.P. continued to hold 73,293 shares after these transactions.
Kathryn Romano reported sales and an intended sale of KRYS common stock. The filing shows 12,500 common shares were sold on 02/09/2026 for $3,401,705.00. It also lists 750 restricted shares tied to vesting as compensation on 02/27/2026.
KRYS reported Form 144 sales by an insider. The filing lists recent sales of Common shares by Daniel S. Janney on 02/24/2026, 02/25/2026, and 02/26/2026, including transactions of 37,895 and 13,825 shares on 02/24/2026. The entries show cash proceeds for each trade in USD.
Krystal Biotech director Daniel Janney reported option exercises and share sales in Krystal Biotech, Inc. common stock. On February 24, 2026, he exercised stock options covering 37,895 shares and received the same number of common shares, then sold those shares in multiple open-market transactions.
On February 24 and 26, 2026, additional open-market sales were reported in accounts indirectly holding shares for Alta Bioequities, L.P., which is managed by an affiliated general partner. The filing notes that Janney’s option exercise and sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 25, 2025. After these trades, 85,096 shares were held indirectly through Alta Bioequities, L.P., while no shares were held directly.
KRYS affiliate files Form 144 to sell common stock. The filing lists proposed/reported sales by Daniel S. Janney consisting of 37,895 shares, 13,825 shares and 700 shares with aggregate cash proceeds reported as $10,113,354.42, $3,709,850.15 and $192,500, respectively. Dates shown for the transactions are 02/24/2026 and 02/25/2026.
KRYS filing a Form 144 notice reports proposed sales of common stock by Daniel S. Janney. The filing lists a proposed sale of 37,895 shares for $10,113,354.42 and a proposed sale of 13,825 shares for $3,709,850.15, both dated 02/24/2026.
KRYS submitted a Form 144 notifying a proposed sale of Common stock, listing 37,895 shares to be sold through Fidelity Brokerage Services LLC by 02/24/2026 with a sale method labeled Cash.
The filing also shows securities sold during the past three months: 13,825 Common shares by Daniel S. Janney on 02/24/2026 for $3,709,850.15.
KRYS: Form 144 sale notice by Daniel S Janney for $10,113,354.42 proceeds on 02/24/2026. The filing lists the sale of 37,895 common shares and identifies the issuer contact as Merrill Lynch, 555 California Street, San Francisco. The securities trace to a private placement dated 08/25/2017.
Krystal Biotech, Inc. director Dino A. Rossi reported option exercises and related share sales. On February 19, 2026, he exercised stock options for 18,950 shares of common stock at $8.79 per share. The options vested ratably over four years beginning on June 1, 2018. On the same date, he sold 8,116 shares at $260.4858 and 10,834 shares at $262.10 in open-market transactions, totaling 18,950 shares sold. After these trades, he directly owned 78,691 shares of Krystal Biotech common stock.